For its stellar performance during the past financial year, Sirion Biotech GmbH (SIRION), a specialist viral vector supplier, has been awarded a coveted Gold Stevie® American Business Award.
The Gold Award, awarded to the top-ranking nominee in each category as judged by 230 professionals worldwide, was recognition of SIRION’s achievement in posting record growth and profit results.
Expansion plans
SIRION Biotech GmbH was judged the Fastest Growing Company of the Year in the nomination Fastest Growing Company of the Year – Up to 100 Employees. In February, SIRION Biotech GmbH released preliminary results for FY ending December 31, 2019, showing a growth of more than 50 per cent over the previous year with service and licensing revenues exceeding USD 11.2m and the company’s intellectual property included in more than 10 clinical programs by leading drug developers.
SIRION also plans continued expansion of its Paris site.
Optimised viral vector engineering
Significant factors underpinning SIRION’s success and record revenues are increasing market need for viral vectors in general and increased number of customer requests, recognising the high quality of the SIRION’s adenovirus, lentivirus, and adenovirus-associated virus (AAV) vectors in particular.
SIRION will receive its award at the 18th American Business Awards, conducted via a virtual awards ceremony on 5 August.
For more information, please fill out the enquiry form attached to this page.